Denosumab Receives Conditional Approval from FDA Expert Panel

October 2009
Internal Medicine Alert;10/16/2009 Supplement, p2
The article reports on the conditional approval given by the Food & Drug Administration (FDA) Expert Panel to the use of Denosumab human monoclonal antibody for the treatment of osteoporosis in the U.S.


Related Articles

  • Denosumab best value for osteoporosis in Belgium.  // PharmacoEconomics & Outcomes News;6/26/2010, Issue 606, p6 

    The article discusses research on the cost effectiveness of the monoclonal antibody denosumab compared with oral bisphosphonates for treating osteoporosis in postmenopausal women in Belgium, referencing a study by M. Hiligsmann and colleagues presented at the 2010 International Osteoporosis...

  • Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases. Tanaka, Toshio; Ogata, Atsushi; Narazaki, Masashi // Clinical Medicine Insights: Therapeutics;2013, Issue 5, p33 

    Interleukin-6 (IL-6), produced by a variety of cells, is a typical cytokine featuring redundancy and pleiotropic activity. IL-6 is promptly and transiently synthesized in response to infections or injuries, and participates in host defense by inducing immune responses, hematopoiesis, and...

  • Clinical: Journals Watch - Osteoporosis, AF and fractures. Newson, Louise // GP: General Practitioner;9/4/2009, p25 

    The article reports that according to a study, Denosumab, a human monoclonal antibody to the receptor activator of the nuclear factor-kappa B ligand (RANKL), is considered as a potential new treatment for osteoporosis. The study involved about 8,000 women between 60 and 90 years old who had a...

  • What's new in Women's health. Hope, Sally // Pulse;3/10/2010, Vol. 70 Issue 8, p20 

    The article offers updates related to women's health in Great Britain. Monoclonal antibody denosumab is an effective treatment for osteoporosis. Intravaginal estrogen pessaries or creams are commonly used by postmenopausal women to avoid symptomatic vaginal atrophy. A menopause pathway published...

  • Monoclonal antibody desensitization in a patient with a generalized urticarial reaction following denosumab administration. Gutiérrez-Fernández, D.; Cruz, María-Jesús; Foncubierta-Fernández, A.; Moreno-Ancillo, A.; Fernández-Anguita, M. J.; Medina-Varo, F.; Andres-García, J. A. // Allergy, Asthma & Clinical Immunology;10/26/2015, Vol. 11, p1 

    Denosumab is a human monoclonal antibody indicated for the treatment of osteoporosis in postmenopausal women with a high risk of fractures. To our knowledge, no cases of desensitization to this drug have been described in the literature. We report the first case of generalized urticarial...

  • A view at monoclonal antibodies in therapy of osteoporosis. Michałowska, Małgorzata; Znorko, Beata; Oksztulska-Kolanek, Ewa; Kamiński, Tomasz; Pawlak, Dariusz // Polish Annals of Medicine / Rocznik Medyczny;Sep2015, Vol. 22 Issue 2, p149 

    Introduction Osteoporosis is a bone disease, which leads to increased fracture risk and weakens bone strength. Drugs used in current therapies of this disease are far from perfect thus the search for new effective compounds is an ongoing process, and some researchers put great hopes in...

  • Impact of denosumab on bone massin cancer patients. Brown-Glaberman, Ursa; Stopeck, Alison T. // Clinical Pharmacology;2013, Vol. 5, p117 

    Cancer therapy-induced bone loss (CTIBL) is a form of secondary osteoporosis associated with systemic chemotherapy and hormonal ablation therapy. The monitoring and treatment of CTIBL is an important component of comprehensive cancer care, especially for patients with curable disease and long...

  • Denosumab Receives Conditional Approval from FDA Expert Panel.  // Primary Care Reports;Oct2009 Supplement, p2 

    The article reports that the a conditional approval has been given to denosumab by the Food and Drug Administration (FDA) Expert Panel in the U.S. The human monoclonal antibody is being reviewed by the agency for its efficacy in treating osteoporosis. One industry-sponsored study found that the...

  • Denosumab Receives Conditional Approval from FDA Expert Panel. Elliott, William T. // Neurology Alert;Oct2009 Pharmacology Watch, p2 

    The article reports that a condition approval has been given to Denosumab, a new human monoclonal antibody, by a Food and Drug Administration (FDA) Expert Panel. The agency is testing the drug for treatment of osteoporosis in men and women. The drug would be branded as Proliaâ„¢ by Amgen...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics